From Dog

Vinblastine is a tubulin-binding mitotic inhibitor chemotherapy agent. It is a chemical analogue of vincristine, with similar antitumor activity.

It is primarily used in combination multidrug therapies against canine lymphoma, transitional cell carcinoma[1] and in combination with toceranib, nitrosourea and prednisolone[2] against mast cell tumors[3], with variable results[4].

Originally used in the MOPP protocol, it is now frequently used with adriamycin, doxorubicin, bleomycin and dacarbazine.

Recommended dose rate in dogs is 2 - 4 mg/m2 every 7 - 14 days, given intravenously. Regular monitoring of CBC is recommended.


  1. Arnold EJ et al (2011) Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 25(6):1385-1390
  2. Rassnick KM et al (2010) A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol 8(2):138-152
  3. Robat C et al (2012) Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012 Sep;10(3):174-83
  4. O'Connell K & Thomson M (2013) Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. Vet Comp Oncol 11(1):51-62